An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer.

ABSTRACT:

Background

the decision whether to treat patients with non-metastatic colon cancer with adjuvant chemotherapy is determined by clinical staging, frequently resulting in over or undertreatment.

Methods

gene expression data and clinical information from 232 stage 1-4 colon cancer patients were analysed to identify expression patterns predictive of recurrence. The signature was evaluated on an independent series of 60 stage 2 and 3 patients. Multivariate analyses were performed to assess the clinical utility of the assay.

Results

a 163-probe signature was able to stratify patients into high- and low-risk groups for disease-free survival (DFS) in both the training and validation series (stage 2: P0.031, stage 3: P0.057) and for disease-specific survival in the training

SUBMITTER: Van Laar RK 

PROVIDER: S-EPMC3008603 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature